Compare MDU & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDU | ACAD |
|---|---|---|
| Founded | 1924 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | MDU | ACAD |
|---|---|---|
| Price | $18.39 | $25.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | $21.67 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.49 | 0.20 |
| Revenue | ★ $1,875,066,000.00 | $726,437,000.00 |
| Revenue This Year | $7.52 | $18.80 |
| Revenue Next Year | $6.00 | $11.70 |
| P/E Ratio | ★ $37.88 | $132.05 |
| Revenue Growth | 6.66 | ★ 40.45 |
| 52 Week Low | $17.01 | $19.69 |
| 52 Week High | $22.98 | $30.96 |
| Indicator | MDU | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 26.72 | N/A |
| Support Level | $18.47 | N/A |
| Resistance Level | $21.08 | N/A |
| Average True Range (ATR) | 0.34 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 4.45 | 0.00 |
MDU Resources Group Inc is a pure-play regulated energy delivery business. It is organized into three reportable business segments: Electric, Natural Gas Distribution, and Pipeline. Maximum revenue is generated from the Pipeline segment, which provides natural gas transportation and underground storage services through a FERC-regulated pipeline system mainly in the Rocky Mountain and northern Great Plains regions of the United States. This segment also provides non-regulated energy-related services, including cathodic protection. The electric segment generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming, and the natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.